Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 6/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.36 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22507880 | 0.83 | S1PR3 (0.48) | HPGDALDH1A1SMN1; SMN2MAPTAR | |
| SCHEMBL16978031 | 0.81 | S1PR3 (0.47) | ERN1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL6970906 | 0.80 | PKM (0.46) | HPGDALDH1A1MAPT | |
| SCHEMBL3813890 | 0.79 | VNN1 (0.42) | ERN1HPGDALDH1A1SMN1; SMN2PDK2 | |
| SCHEMBL1267736 | 0.78 | KDM4E (0.57) | HPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL8143064 | 0.78 | AR (0.44) | HPGDALDH1A1SMN1; SMN2HSP90AA1PDK1 | |
| SCHEMBL4021525 | 0.78 | HPGD (0.41) | HPGDALDH1A1SMN1; SMN2PDK2HSP90AA1 | |
| SCHEMBL9131982 | 0.77 | CA12 (0.56) | ERN1HPGDALDH1A1SMN1; SMN2PDK2 | |
| SCHEMBL19682731 | 0.76 | AR (0.41) | HPGDALDH1A1SMN1; SMN2PDK2PDK1 | |
| SCHEMBL2427132 | 0.76 | CA1 (0.62) | ERN1HPGDALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | ERN1 1510/4885HPGD 3054/4885ALDH1A1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.